Therapeutic resistance is a key roadblock to effective cancer treatment and can occur through various mechanisms. A recent study characterized a previously unknown, reversible mechanism of drug resistance mediated by an altered chromatin state, suggesting that cancer cell populations can use a dynamic strategy to ensure their survival when challenged by therapeutic intervention.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer
Journal of Translational Medicine Open Access 05 September 2022
-
α-Amanitin Restrains Cancer Relapse from Drug-Tolerant Cell Subpopulations via TAF15
Scientific Reports Open Access 16 May 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hoey, T. Sci. Transl. Med. 2, 28ps19 (2010).
Sawyers, C.L. Nat. Med. 15, 1158–1161 (2009).
Engelman, J.A. & Janne, P.A. Clin. Cancer Res. 14, 2895–2899 (2008).
Cohen, A.A. et al. Science 322, 1511–1516 (2008).
Bird, A. Genes Dev. 16, 6–21 (2002).
Sharma, S.V. et al. Cell 141, 69–80 (2010).
Jones, P.A. & Baylin, S.B. Cell 128, 683–692 (2007).
Reya, T., Morrison, S.J., Clarke, M.F. & Weissman, I.L. Nature 414, 105–111 (2001).
Klose, R.J. et al. Cell 128, 889–900 (2007).
Gaymes, T.J. et al. Mol. Cancer Res. 4, 563–573 (2006).
Johnstone, S.E. & Baylin, S.B. Nat. Rev. Genet. 11, 806–812 (2010).
Mikkelsen, T.S. et al. Nature 454, 49–55 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Baylin, S. Resistance, epigenetics and the cancer ecosystem. Nat Med 17, 288–289 (2011). https://doi.org/10.1038/nm0311-288
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm0311-288
This article is cited by
-
The potential applications of microparticles in the diagnosis, treatment, and prognosis of lung cancer
Journal of Translational Medicine (2022)
-
Histone deacetylase inhibitor targets CD123/CD47-positive cells and reverse chemoresistance phenotype in acute myeloid leukemia
Leukemia (2019)
-
Phosphorylation of cofilin-1 by ERK confers HDAC inhibitor resistance in hepatocellular carcinoma cells via decreased ROS-mediated mitochondria injury
Oncogene (2017)
-
Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles
Cell Research (2016)
-
α-Amanitin Restrains Cancer Relapse from Drug-Tolerant Cell Subpopulations via TAF15
Scientific Reports (2016)